Jianming Hu
- Cancer Research top 5%
- MicroRNA in disease regulation 11
- Cancer-related molecular mechanisms research 11
- Molecular Biology top 10%
- RNA modifications and cancer 15
- Cancer-related gene regulation 12
- Epigenetics and DNA Methylation 7
- Oncology top 10%
- Cancer Cells and Metastasis 9
- Otorhinolaryngology top 10%
-
- Esophageal Cancer Research and Treatment 17
-
- Sarcoma Diagnosis and Treatment 8
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
Jianming Hu
65 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Cancer Research 544
- Molecular Biology 958
- Oncology 334
- Immunology 207
- Otorhinolaryngology 32
Countries citing papers authored by Jianming Hu
This map shows the geographic impact of Jianming Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianming Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianming Hu more than expected).
Fields of papers citing papers by Jianming Hu
This network shows the impact of papers produced by Jianming Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianming Hu. The network helps show where Jianming Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jianming Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 11 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 32 | |
| 4 | 2024 | 13 | |
| 5 | 2023 | 12 | |
| 6 | 2023 | 22 | |
| 7 | 2022 | 3 | |
| 8 | 2021 | 55 | |
| 9 | 2021 | 9 | |
| 10 | 2021 | 13 | |
| 11 | 2019 | 29 | |
| 12 | Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expressionbreakdown → | 2019 | 306 |
| 13 | 2019 | 20 | |
| 14 | 2017 | 9 | |
| 15 | 2016 | 46 | |
| 16 | 2015 | 11 | |
| 17 | 2015 | 19 | |
| 18 | 2015 | 16 | |
| 19 | 2013 | 12 | |
| 20 | 2013 | 37 |
About Jianming Hu
Jianming Hu is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 67 papers that have together received 1.5k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (17 papers), RNA modifications and cancer (15 papers), Cancer-related gene regulation (12 papers), MicroRNA in disease regulation (11 papers), Cancer-related molecular mechanisms research (11 papers), Cancer Cells and Metastasis (9 papers), Sarcoma Diagnosis and Treatment (8 papers) and Epigenetics and DNA Methylation (7 papers). The work is most often cited by research in Cancer Research (544 citations), Molecular Biology (958 citations) and Oncology (334 citations). Jianming Hu has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Xiaobin Cui, Yunzhao Chen, Chunxia Liu, Lijuan Pang, Lan Yang, Weihua Liang, Xueping Han, Lan Yang, Hong Zhou and Hao Peng. Their work appears in journals such as ACS Nano, PLoS ONE and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.